Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Smyth

Showing results (41-50 of 379) with videos related to

Pageof 38
Sort By:
Current Opinion in Oncology|June 17, 2020
Multimodality treatment for localized gastric cancer: state of the art and new insightsAngelica Petrillo, Elizabeth C Smyth
The Lancet. Oncology|January 9, 2025
Expanding therapeutic options targeting claudin-18.2Katharine Herbert, Elizabeth C Smyth
Current Treatment Options in Oncology|May 4, 2012
Targeted therapy for gastric cancerElizabeth C Smyth, David Cunningham
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expectedC Connell, E C Smyth
World Journal of Gastrointestinal Oncology|June 18, 2014
Operable gastro-oesophageal junctional adenocarcinoma: Where to next?Elizabeth C Smyth, David Cunningham
Health Care for Women International|November 1, 1994
A case study of an abused older womanC A Mitchell, C Smyth
The Lancet. Oncology|May 10, 2016
Encouraging results for PD-1 inhibition in gastric cancerElizabeth C Smyth, David Cunningham
Nature Reviews. Clinical Oncology|January 9, 2013
Gastric cancer in 2012: Defining treatment standards and novel insights into disease biologyElizabeth C Smyth, David Cunningham
Nature Reviews. Clinical Oncology|December 22, 2018
Two steps forward and one step backFlorian Lordick, Elizabeth C Smyth
Lancet (London, England)|October 23, 2023
Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancerElizabeth C Smyth, Raghav Sundar
Pageof 38

Showing results (41-50 of 379) with videos related to

Sort By:
Pageof 38
Current Opinion in Oncology|June 17, 2020
Multimodality treatment for localized gastric cancer: state of the art and new insightsAngelica Petrillo, Elizabeth C Smyth
The Lancet. Oncology|January 9, 2025
Expanding therapeutic options targeting claudin-18.2Katharine Herbert, Elizabeth C Smyth
Current Treatment Options in Oncology|May 4, 2012
Targeted therapy for gastric cancerElizabeth C Smyth, David Cunningham
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expectedC Connell, E C Smyth
World Journal of Gastrointestinal Oncology|June 18, 2014
Operable gastro-oesophageal junctional adenocarcinoma: Where to next?Elizabeth C Smyth, David Cunningham
Health Care for Women International|November 1, 1994
A case study of an abused older womanC A Mitchell, C Smyth
The Lancet. Oncology|May 10, 2016
Encouraging results for PD-1 inhibition in gastric cancerElizabeth C Smyth, David Cunningham
Nature Reviews. Clinical Oncology|January 9, 2013
Gastric cancer in 2012: Defining treatment standards and novel insights into disease biologyElizabeth C Smyth, David Cunningham
Nature Reviews. Clinical Oncology|December 22, 2018
Two steps forward and one step backFlorian Lordick, Elizabeth C Smyth
Lancet (London, England)|October 23, 2023
Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancerElizabeth C Smyth, Raghav Sundar
Pageof 38